252 related articles for article (PubMed ID: 12209148)
1. Phosphodiesterase 5 inhibitors: current status and potential applications.
Rotella DP
Nat Rev Drug Discov; 2002 Sep; 1(9):674-82. PubMed ID: 12209148
[TBL] [Abstract][Full Text] [Related]
2. PDE-5 inhibitors: current status and future trends.
Masson P; Lambert SM; Brown M; Shabsigh R
Urol Clin North Am; 2005 Nov; 32(4):511-25, viii. PubMed ID: 16291042
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
Vickers MA; Satyanarayana R
Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
5. Tadalafil (Cialis) for men with erectile dysfunction.
Eardley I; Cartledge J
Int J Clin Pract; 2002 May; 56(4):300-4. PubMed ID: 12074215
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of phosphodiesterase-5 inhibitors.
Corbin JD; Francis SH
Int J Clin Pract; 2002; 56(6):453-9. PubMed ID: 12166544
[TBL] [Abstract][Full Text] [Related]
7. Oral drug treatment of erectile dysfunction.
Int J Impot Res; 2003 Dec; 15 Suppl 7():S27-9. PubMed ID: 14695970
[No Abstract] [Full Text] [Related]
8. [New PDE-5 inhibitor for treatment of impotence. 9 out of 10 have erections again].
MMW Fortschr Med; 2003 Jun; 145(26):59. PubMed ID: 12916343
[No Abstract] [Full Text] [Related]
9. Tadalafil and vardenafil.
Neumeyer K; Kirkpatrick P
Nat Rev Drug Discov; 2004 Apr; 3(4):295-6. PubMed ID: 15124623
[No Abstract] [Full Text] [Related]
10. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Gresser U; Gleiter CH
Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
[TBL] [Abstract][Full Text] [Related]
11. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
Gupta M; Kovar A; Meibohm B
J Clin Pharmacol; 2005 Sep; 45(9):987-1003. PubMed ID: 16100293
[TBL] [Abstract][Full Text] [Related]
12. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
Ströberg P; Hedelin H; Ljunggren C
Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
[TBL] [Abstract][Full Text] [Related]
13. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
14. [Phosphodiesterase inhibitors: effectiveness and new applications].
van Driel MF
Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1613-6. PubMed ID: 16901064
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of phosphodiesterase 5 inhibitors.
Carrier S
Can J Urol; 2003 Feb; 10 Suppl 1():12-6. PubMed ID: 12625845
[TBL] [Abstract][Full Text] [Related]
16. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
Doggrell S
Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
[TBL] [Abstract][Full Text] [Related]
17. Treatment of erectile dysfunction.
Dinsmore W
Int J STD AIDS; 2004 Apr; 15(4):215-21. PubMed ID: 15075013
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Kloner RA
Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
Dunn ME; Althof SE; Perelman MA
Int J Impot Res; 2007; 19(2):119-23. PubMed ID: 16738695
[TBL] [Abstract][Full Text] [Related]
20. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
Rosen RC; McKenna KE
Annu Rev Sex Res; 2002; 13():36-88. PubMed ID: 12836729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
